Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Amortization - Intangibles (2023 - 2025)

Prime Medicine's Amortization - Intangibles history spans 3 years, with the latest figure at $858000.0 for Q4 2025.

  • For Q4 2025, Amortization - Intangibles rose 180.39% year-over-year to $858000.0; the TTM value through Dec 2025 reached $2.5 million, down 29.31%, while the annual FY2025 figure was $2.5 million, 29.31% down from the prior year.
  • Amortization - Intangibles reached $858000.0 in Q4 2025 per PRME's latest filing, up from $752000.0 in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $2.0 million in Q2 2023 to a low of $306000.0 in Q4 2024.
  • Average Amortization - Intangibles over 3 years is $985909.1, with a median of $858000.0 recorded in 2025.
  • Peak YoY movement for Amortization - Intangibles: plummeted 72.82% in 2024, then soared 180.39% in 2025.
  • A 3-year view of Amortization - Intangibles shows it stood at $1.1 million in 2023, then tumbled by 72.82% to $306000.0 in 2024, then surged by 180.39% to $858000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Amortization - Intangibles are $858000.0 (Q4 2025), $752000.0 (Q3 2025), and $530000.0 (Q2 2025).